Nanophase Technologies Reports Record Financial Results for Third Quarter Ended September 30, 2021

Rhea-AI Summary

Nanophase Technologies (OTCQB: NANX) reported a record third quarter with an impressive 80% year-over-year growth. For the nine months ending September 30, 2021, revenue reached $22.1 million, exceeding the full year 2020 revenue by 98%. The Solésence product line saw a remarkable growth of 204% to $13.4 million. Income from operations increased to $2.9 million, with a net income of $2.7 million, or $0.04 per share. The company anticipates continued growth through 2022, bolstered by existing purchase orders worth $27 million.

Positive

• 80% year-over-year growth in Q3 revenue.
• Nine-month revenue of $22.1 million exceeds full year 2020 revenue by 98%.
• Solésence revenue rose by 204% to $13.4 million.
• Income from operations increased to $2.9 million.
• Net income improved to $2.7 million or $0.04 per share.
• Purchase orders exceeding $27 million expected to drive 2022 growth.

Negative

• Advanced Materials revenue decreased by 8% to $3.4 million.
• Demand for medical diagnostics materials has softened post-pandemic.

• Announces Another Record Quarter with 80% YOY Growth

• Delivered $22 Million in Nine-Month Revenue

• Solésence Nine-Month 2021 Revenue Exceeded Full Year 2020
  Revenue by More Than 98%

ROMEOVILLE, Ill., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Nanophase Technologies Corporation (OTCQB: NANX), a leader in minerals-based and scientifically-driven health care solutions across beauty and life science categories — with innovations that protect skin from environmental aggressors and aid in medical diagnostics — today announced financial results for its third quarter and nine months ended September 30, 2021.

“Through executing our growth strategy, we have seen accelerated consumer adoption of our Solésence products, as well as returning demand for our Active Pharmaceutical Ingredients (“APIs”) sold in to sun- and skin-care applications. We are continuing to develop new technologies and create exciting product applications for our novel beauty science platforms,” said Jess Jankowski, Chief Executive Officer. “Solésence beauty science sees triple-digit growth as our products continue to be embraced by our brand partners, and we expect this growth to continue through 2022. Through our largest personal care ingredients customer, we have seen growth in sales of our APIs eclipse full year 2020 levels through October 2021, and we expect to see continued growth in 2022. Demand for our medical diagnostics materials has softened after the first half of 2021, which we believe relates to the moderation in the current pandemic environment. We continue to believe that our novel materials technology enables enhanced performance in helping diagnosticians to identify COVID-19 and other viruses more accurately. Life science will remain the third major component of our business strategy going forward,” Jankowski added:

“After delivering more than $22M in revenue during the first nine months, we still had purchase orders in hand for another $27M+ taking us well in to 2022. Approximately $10M of this applies to 2021 customer orders, the majority of which we expect to fulfill prior to 2022.”

“Our results reflect our strong position relative to two dominant trends in the beauty industry: the rapid evolution toward clean and more inclusive products and the desire to simplify beauty regimes. The clean evolution builds on the premise that safer products will lead to more beautiful and healthy skin and a healthier planet, while the Pandemic-driven trend of simplifying beauty regimens has highlighted the need for technologies that can be multifunctional — offering a single formula with a combination of benefits that are commonly achieved by two or three separate products. Our technologies. and the products we build from them in both our API and Solésence businesses, serve as the core to brands successfully addressing the consumer’s needs driven by both these trends. As a result, our company will enjoy more than a dozen new product launches in 2022, underpinning Nanophase’s ability to continue solid growth in the future,” said Kevin Cureton, Chief Operating Officer.

Third Quarter and YTD 2021 Financial Highlights
(All Numbers are Approximate)

•  Revenue for the third quarter was $7.9 million, vs. $3.9 million for the same period in 2020. Revenue for the nine months ended September 30, 2021 was $22.1 million, vs. $12.3 million for the same period in 2020.

For the nine-month period of 2021:

• Solésence beauty science nine-month revenue was $13.4 million, up 204% from $4.4 million for the same period in 2020.
  • Solésence nine-month 2021 revenue exceeded full year 2020 Solésence revenue by more than 98%.
• Advanced Materials revenue was $3.4 million, down 8% from $3.7 million in the same period of 2020.
• Personal Care Ingredients revenue was $5.3 million, up 28% from $4.2 million in 2020.

•  Income from operations, before interest expense and other income, was $2.9 million for the nine-month period in 2021, versus $1.2 million for the same period in 2020.

•  Net income for the nine-month period ended September 30, 2021 was $2.7 million in 2021, compared to $0.8 million for the same period in 2020, reflecting a $0.04 per share improvement period over period.

•  The Company finished the quarter with approximately $1.4 million in cash.

Jankowski concluded: “Our largest current challenges involve expanding our business to meet existing and future demand. We are hard at work to facilitate and manage this expansion, with confidence that it will support continued, if not accelerated, growth. We remain steadfast in our vision to enhance people’s lives through better health — with science and innovation as our pathway to get there. We are committed to doing our part to improve public health by providing essential products for the health and safety of those we serve.”

Conference Call
Nanophase will host its Third quarter 2021 conference call on Thursday, November 4, 2021, at 10:00 a.m. CDT, 11:00 a.m. EDT to discuss its financial results and provide a business and financial update.

Click here to listen to the live webcast of the event, or dial in using the number(s) below:

	U.S.:	(877) 312-8776
	International:	(408) 774-4007

The conference ID is 6190086.

Please dial in to the conference call at least 5 minutes prior to the scheduled start of the call to avoid connection delays. If a participant will be listen-only, they are encouraged to listen via the webcast after the call.

The call may also be accessed through the company’s website, at www.nanophase.com, by clicking on Investor Relations, Investor News and the link in this Press Release.

FINANCIAL RESULTS AND NON-GAAP INFORMATION

Use of Non-GAAP Financial Information
Nanophase believes that the presentation of results excluding certain items, such as non-cash equity compensation charges, provides meaningful supplemental information to both management and investors, facilitating the evaluation of performance across reporting periods. The Company uses these non-GAAP measures for internal planning and reporting purposes. These non-GAAP measures are not in accordance with, or an alternative for, Generally Accepted Accounting Principles (“GAAP”) and may be different from non-GAAP measures used by other companies. The presentation of this additional information is not meant to be considered in isolation or as a substitute for net income or net income per share prepared in accordance with GAAP.

About Nanophase Technologies
Nanophase Technologies Corporation (NANX), www.nanophase.com, is a leading innovator in minerals-based and scientifically driven health care solutions across beauty and life science categories, as well as other legacy advanced materials applications. Leveraging a platform of integrated, patented, and proprietary technologies, the Company creates products with unique performance, enhancing consumers health and well-being. We deliver commercial quantity and quality engineered materials both as ingredients and as part of fully formulated products in a variety of formats.

Forward-Looking Statements
This press release contains words such as “expects,” “shall,” “will,” “believes,” and similar expressions that are intended to identify forward-looking statements within the meaning of the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. Such statements in this announcement are made based on the Company’s current beliefs, known events and circumstances at the time of publication, and as such, are subject in the future to unforeseen risks and uncertainties that could cause the Company’s results of operations, performance, and achievements to differ materially from current expectations expressed in, or implied by, these forward-looking statements. These risks and uncertainties include, without limitation, the following: a decision by a customer to cancel a purchase order or supply agreement in light of the Company’s dependence on a limited number of key customers; uncertain demand for, and acceptance of, the Company’s engineered materials, ingredients, and fully formulated products; the Company’s manufacturing capacity and product mix flexibility in light of customer demand; the Company’s limited marketing experience; changes in development and distribution relationships; the impact of competitive products and technologies; the Company’s dependence on patents and protection of proprietary information; the resolution of litigation in which the Company may become involved; the impact of any potential new government regulations that could be difficult to respond to or too costly to comply with while remaining financially viable; the ability of the Company to maintain an appropriate electronic trading venue; and other factors described in the Company’s Form 10-K filed March 26, 2021. In addition, the Company’s forward-looking statements could be affected by general industry and market conditions and growth rates. Except as required by federal securities laws, the Company undertakes no obligation to update or revise these forward-looking statements to reflect new events, uncertainties, or other contingencies.

COMPANY CONTACT
Investor Relations
630-771-6700

NANOPHASE TECHNOLOGIES CORPORATION
CONSOLIDATED BALANCE SHEETS
(in thousands except share and per share data)
			September				December 31,
				2021				2020
ASSETS			(Unaudited)
Current assets:
	Cash		$	1,380			$	957
	Trade accounts receivable, less allowance for doubtful accounts of $9
		for both September 30, 2021 and December 31, 2020		4,723				2,932
	Inventories, net			6,327				4,340
	Prepaid expenses and other current assets			698				606
		Total current assets		13,128				8,835
	Equipment and leasehold improvements, net			4,014				2,868
	Operating leases, right of use			1,679				1,827
	Other assets, net			9				10
			$	18,830			$	13,540
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
	Line of credit, bank		$	-			$	500
	Line of credit, related party			3,740				2,155
	Current portion of long-term debt, related party			1,000				500
	Current portion of finance lease obligations			137				177
	Current portion of operating lease obligations			521				431
	Accounts payable			2,436				2,126
	Deferred revenue			388				411
	Accrued expenses			1,251				484
		Total current liabilities		9,473				6,784
	Long-term portion of finance lease obligations			11				110
	Long-term portion of operating lease obligations			1,385				1,651
	Long-term convertible loan, related party			-				1,097
	PPP Loan (SBA)			-				952
	Asset retirement obligation			220				214
		Total long-term liabilities		1,616				4,024
Contingent liabilities				-				-
Stockholders’ equity:
	Preferred stock, $.01 par value, 24,088 shares authorized and
		no shares issued and outstanding		-				-
	Common stock, $.01 par value, 55,000,000 shares authorized;
		48,725,473 and 38,221,292 shares issued and outstanding on September 30, 2021
		and December 31, 2020, respectively		487				382
	Additional paid-in capital			104,307				102,117
	Accumulated deficit			(97,053	)			(99,767	)
		Total stockholders’ equity		7,741				2,732
			$	18,830			$	13,540

NANOPHASE TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
					Three months ended						Nine months ended
					September 30,						September 30,
					2021			2020			2021				2020
Revenue:
	Product revenue				$	7,896		$	3,827		$	21,971			$	11,929
	Other revenue					28			61			139				333
		Net revenue				7,924			3,888			22,110				12,262
Operating expense:
	Cost of revenue					4,946			2,201			14,588				7,832
		Gross profit				2,978			1,687			7,522				4,430
	Research and development expense					635			405			1,670				1,134
	Selling, general and administrative expense					942			730			2,994				2,133
Income from operations						1,401			552			2,858				1,163
Interest expense						38			122			1,096				368
Other income, net						-			-			(952	)			-
Income before provision for income taxes						1,363			430			2,714				795
Provision for income taxes						-			-			-				-
Net income					$	1,363		$	430		$	2,714			$	795
Net income per share-basic					$	0.03		$	0.01		$	0.06			$	0.02
Weighted average number of common shares outstanding - basic						48,566,431			38,141,741			43,756,300				38,138,453
Net income per share-diluted					$	0.03		$	0.01		$	0.06			$	0.02
Weighted average number of common shares outstanding - diluted						50,728,431			38,432,741			45,726,300				38,228,453
NANOPHASE TECHNOLOGIES CORPORATION
CONSOLIDATED STATEMENTS OF OPERATIONS - EXPANDED SCHEDULE
(Unaudited Consolidated Condensed)
(in thousands except share and per share data)
					Three months ended						Nine months ended
					September 30,						September 30,
					2021			2020			2021				2020
Revenue:
	Product revenue				$	7,896		$	3,827		$	21,971			$	11,929
	Other revenue					28			61			139				333
		Net revenue				7,924			3,888			22,110				12,262
Operating expense:
	Cost of revenue detail:
	Depreciation					103			74			283				218
	Non-Cash equity compensation					4			19			15				38
	Other costs of revenue					4,839			2,108			14,290				7,576
		Cost of revenue				4,946			2,201			14,588				7,832
			Gross profit			2,978			1,687			7,522				4,430
	Research and development expense detail:
	Depreciation					9			10			27				32
	Non-Cash equity compensation					7			14			36				43
	Other research and development expense					619			381			1,607				1,059
		Research and development expense				635			405			1,670				1,134
	Selling, general and administrative expense detail:
	Depreciation and amortization					6			5			18				15
	Non-Cash equity compensation					17			15			72				66
	Other selling, general and administrative expense					919			710			2,904				2,052
		Selling, general and administrative expense				942			730			2,994				2,133
Income from operations						1,401			552			2,858				1,163
Interest expense						38			122			1,096				368
Other income, net						-			-			(952	)			-
Income before provision for income taxes						1,363			430			2,714				795
Provision for income taxes						-			-			-				-
Net income					$	1,363		$	430		$	2,714			$	795
Non-GAAP Disclosure (see note regarding Non-GAAP disclosures):
	Addback Interest, net					38			122			1,096				368
	Addback Depreciation/Amortization					118			89			328				265
	Addback Non-Cash Equity Compensation					28			48			124				147
	Subtract Non-Cash Other Income					-			-			(952	)			-
	Adjusted EBITDA				$	1,547		$	689		$	3,310			$	1,575

FAQ

What were Nanophase Technologies' Q3 2021 earnings results?

Nanophase Technologies reported Q3 2021 revenue of $7.9 million, an increase from $3.9 million in Q3 2020.

How much revenue did Nanophase Technologies generate in the first nine months of 2021?

In the first nine months of 2021, Nanophase Technologies generated $22.1 million in revenue.

What is the outlook for Nanophase Technologies in 2022?

Nanophase Technologies expects continued growth in 2022, supported by over $27 million in purchase orders.

What is the performance of Solésence products in 2021?

Solésence products experienced triple-digit growth, with revenues up by 204% to $13.4 million.

How did the demand for medical diagnostics materials change for Nanophase Technologies?

The demand for medical diagnostics materials softened after the first half of 2021 due to the moderation of the pandemic environment.